Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing mechanistic pathways without original human empirical data or systematic review methodology.
PubMed 34313822 · doi:10.1007/s00424-021-02606-2
What was done
This is a narrative review detailing the mechanistic pathways through which hyperuricemia (serum uric acid > 416 µmol/L) induces endothelial insulin resistance, specifically focusing on the disruption of insulin-stimulated endothelial nitric oxide (NO) synthesis.
What was found
The abstract reports mechanistic pathways and provides no quantitative data or effect sizes. Elevated uric acid is described as impairing insulin-induced NO synthesis via proximal post-receptor disruption of insulin receptor substrate (IRS) and PI3K/Akt signaling, and distal disruption of endothelial nitric oxide synthase (eNOS) via decreased expression, reduced activity, and direct NO inactivation. These molecular disruptions are linked to impaired NO-dependent vasodilation and systemic insulin resistance.
Why it matters
It outlines the cellular mechanisms connecting hyperuricemia to vascular dysfunction and cardiometabolic disease, highlighting potential biological pathways through which uric acid-lowering therapies might improve vascular health.
Limits
As a narrative review, it presents no original experimental data, clinical trials, or systematic search methodology. No quantitative metrics, confidence intervals, sample sizes, or study counts are reported in the abstract. Clinical therapeutic benefits of lowering uric acid on hard cardiovascular outcomes remain mechanistic hypotheses rather than proven effects within this text.
Cited by
- supports Uric acid inhibits nitric oxide production.
- supports Elevated uric acid damages vascular function by inhibiting nitric oxide production.
- supports Uric acid inhibits the activity of endothelial nitric oxide synthase (eNOS).